Yaroslav Staroseletz

Dr. Yaroslav Staroseletz


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ICIvan Chernikov
Ivan Chernikov
YSYaroslav Staroseletz
Yaroslav Staroseletz
ITIrina Sergeevna Tatarnikova
Irina Sergeevna Tatarnikova
ASAleksandra V. Sen'kova
Aleksandra V. Sen'kova
ISInnokenty A. Savin
Innokenty A. Savin
VVValentin Vlassov
Valentin Vlassov
Acute lung injury is a complex cascade process that develops in response to various damaging factors, which can lead to acute respiratory distress syndrome. Within this study, based on bioinformatics reanalysis of available full-transcriptome data of acute lung injury induced in mice and humans by various factors, we selected a set of genes that could serve as good targets for suppressing inflammation in the lung tissue, evaluated their expression in the cells of different origins during LPS-induced inflammation, and chose the tissue inhibitor of metalloproteinase Timp1 as a promising target for suppressing inflammation. We designed an effective chemically modified anti-TIMP1 siRNA and showed that Timp1 silencing correlates with a decrease in the pro-inflammatory cytokine IL6 secretion in cultured macrophage cells and reduces the severity of LPS-induced acute lung injury in a mouse model.

19 March 2021 in Molecules
Verified
Journal Article
Open access
PDF file
YSYaroslav Staroseletz
Yaroslav Staroseletz
SMSvetlana Miroshnichenko
Svetlana Miroshnichenko
OPOlga Patutina
Olga Patutina
Elena V. BichenkovaElena V. Bichenkova
Elena V. Bichenkova
BABahareh Amirloo
Bahareh Amirloo
MZMarina Zenkova
Marina Zenkova
RNA-targeting therapeutics require highly efficient sequence-specific devices capable of RNA irreversible degradation in vivo. The most developed methods of sequence-specific RNA cleavage, such as siRNA or antisense oligonucleotides (ASO), are currently based on recruitment of either intracellular multi-protein complexes or enzymes, leaving alternative approaches (e.g., ribozymes and DNAzymes) far behind. Recently, site-selective artificial ribonucleases combining the oligonucleotide recognition motifs (or their structural analogues) and catalytically active groups in a single molecular scaffold have been proven to be a great competitor to siRNA and ASO. Using the most efficient catalytic groups, utilising both metal ion-dependent (Cu(II)-2,9-dimethylphenanthroline) and metal ion-free (Tris(2-aminobenzimidazole)) on the one hand and PNA as an RNA recognising oligonucleotide on the other, allowed site-selective artificial RNases to be created with half-lives of 0.5–1 h. Artificial RNases based on the catalytic peptide [(ArgLeu)2Gly]2 were able to take progress a step further by demonstrating an ability to cleave miRNA-21 in tumour cells and provide a significant reduction of tumour growth in mice.

18 May 2015 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Open access
YSYaroslav Staroseletz
Yaroslav Staroseletz
EBEvgeney V. Brenner
Evgeney V. Brenner
VVValentin Vlassov
Valentin Vlassov
MZMarina A. Zenkova
Marina A. Zenkova
(2015). 81 Nonenzymatic recombination of RNA: detection of novel sequences by next-generation sequencing. Journal of Biomolecular Structure and Dynamics: Vol. 33, No. sup1, pp. 52-53.